Holen Sie sich die Stockscreener-App
5.18
5.71%
0.28
Vorhandelsmarkt:
4.93
-0.25
-4.83%
Schlusskurs vom Vortag:
$4.90
Offen:
$4.53
24-Stunden-Volumen:
482.24K
Relative Volume:
1.81
Marktkapitalisierung:
$260.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-76.41M
KGV:
-2.6979
EPS:
-1.92
Netto-Cashflow:
$-64.56M
1W Leistung:
-10.69%
1M Leistung:
-7.00%
6M Leistung:
-45.30%
1J Leistung:
-30.93%
1-Tages-Spanne:
$4.345
$5.38
1-Wochen-Bereich:
$4.345
$5.92
52-Wochen-Spanne:
$4.345
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Firmenname
Aura Biosciences Inc
Sektor
Branche
Telefon
(617)500-8864
Adresse
80 GUEST STREET, BOSTON
Vergleichen Sie AURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
5.18 | 291.56M | 0 | -76.41M | -64.56M | -1.92 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 38.69M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
69.53 | 5.64B | 0 | -153.72M | -103.81M | -2.00 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2022-07-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Aktie (AURA) Neueste Nachrichten
Aura Biosciences Launches Public Offering Of Common Stock And Warrants - Nasdaq
Aura Biosciences announces common stock, warrant offering, no amount given - TipRanks
Aura Biosciences Prices $75 Million Offering of Shares, Warrants - marketscreener.com
Aura Biosciences sets terms for $75 million public offering - Investing.com
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants - GlobeNewswire
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants - Benzinga
Aura Biosciences Secures $75M Funding: Major Push for Precision Cancer Treatment Development - Stock Titan
Aura Biosciences Launches Proposed Public Offering of Shares, Warrants - marketscreener.com
Aura Biosciences (AURA) Initiates Public Offering with Multiple Financial Managers | AURA Stock News - GuruFocus
Aura Biosciences Appoints New Chief Financial Officer - TipRanks
Aura Biosciences Announces Proposed Public Offering Of Common Stock And Warrants - marketscreener.com
Aura Biosciences, Inc. SEC 10-Q Report - TradingView
Aura Biosciences Enrolls First Patient in Phase 1b/2 Trial of Bel-sar for Non-Muscle-Invasive Bladder Cancer and Strengthens Leadership Team with New Appointment - Nasdaq
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants - GlobeNewswire
Major Cancer Therapy Developer Aura Biosciences Announces Strategic Public Offering with Top Wall Street Banks - Stock Titan
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Aura Biosciences Hits Major Milestone in Bladder Cancer Trial, Reveals Strong Pipeline Progress - Stock Titan
Dimensional Fund Advisors LP Buys 73,062 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
(AURA) Trading Advice - news.stocktradersdaily.com
Barclays PLC Grows Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Analysts Set Aura Biosciences, Inc. (NASDAQ:AURA) Price Target at $22.75 - Defense World
Wells Fargo & Company MN Buys 5,930 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Aura Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
Clinical-Stage Biotech Aura Biosciences Lines Up 3 Key Investor Conferences: What to Expect - Stock Titan
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Up 37.3% in April - Defense World
(AURA) Proactive Strategies - news.stocktradersdaily.com
Aura Biosciences, Inc. (NASDAQ:AURA) Shares Purchased by JPMorgan Chase & Co. - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Position Increased by Geode Capital Management LLC - Defense World
Oncology’s Most Eligible Unpartnered Assets - insights.citeline.com
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Up 19.3% in March - Defense World
Vanguard Group Inc. Acquires 112,296 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Aura Biosciences SVP Amy Elazzouzi sells $4,924 in stock By Investing.com - Investing.com India
Aura Biosciences SVP sells $4,924 in stock By Investing.com - Investing.com India
Aura Biosciences executive sells $39,319 in stock By Investing.com - Investing.com Canada
Aura Biosciences executive sells $39,319 in stock - Investing.com Australia
Aura Biosciences SVP sells $4,924 in stock - Investing.com
Aura Biosciences SVP Amy Elazzouzi sells $4,924 in stock - Investing.com
Wellington Management Group LLP Has $1.08 Million Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
American Century Companies Inc. Has $392,000 Stake in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Q1 EPS Estimate for Aura Biosciences Decreased by Analyst - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Aura Biosciences stock hits 52-week low at $5.05 - Investing.com Australia
Aura Biosciences stock hits 52-week low at $5.05 By Investing.com - Investing.com South Africa
Is Aura Biosciences (AURA) The Small Cap Stock with Huge Upside Potential? - Insider Monkey
10 Small Cap Stocks with Huge Upside Potential - Insider Monkey
Aura Biosciences expands board with oncology leader By Investing.com - Investing.com South Africa
Aura Biosciences Appoints Teresa Bitetti To Board - citybiz
Aura Biosciences Announces Appointment Of Teresa Bitetti To Board Of Directors - MarketScreener
Aura Biosciences Expands Board with New Director Appointment - TipRanks
Aura Biosciences expands board with oncology leader - Investing.com
Finanzdaten der Aura Biosciences Inc-Aktie (AURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.17%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):